Trial
NCT00698685
Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Arizona
Collaborators
National Cancer Institute (NCI)
Condition
Leukemia
Intervention
Pentostatin
Why stopped
Pentostatin/alemtuzumab regimen had greater risk of graft failure.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-03-31